Corporate Travel Management: Stepping up to the majors
About the author:
- Author name:
- By Belinda Moore
- Job title:
- Senior Analyst
- Date posted:
- 26 October 2020, 4:20 PM
- Sectors Covered:
- Agriculture, Food & Beverage, Travel
- CTD recently announced the acquisition of Travel & Transport (T&T) in the US.
When combined with CTD’s existing North American business, the company will
have material scale in this key growth market.
- When travel demand recovers post COVID-19 (we assume FY23), CTD should
achieve its A$10bn TTV target with the addition of T&T. It will also become the fifth
largest corporate travel company in the world. The acquisition is highly accretive.
- CTD remains our key pick in the travel sector. We resume coverage with an Add
rating (login to view more). From here, key share price catalysts include its
AGM trading update, borders reopening, rapid COVID-19 testing at airports,
success in vaccine development and further accretive M&A opportunities.
Acquisition of Travel & Transport - will transform US business
On 30 October, CTD will acquire Travel & Transport (T&T), a leading corporate travel
company in the US. Strategically, this acquisition is highly compelling. It provides CTD
with its targeted level of scale and will make it the fifth largest player in the market and the
biggest in the mid-market. The businesses complement each other with T&T’s strong
position on the East Coast and its largely professional services and healthcare client base.
When travel normalises the combined businesses will have TTV over A$5.2bn in the US
and CTD’s market share in the US corporate travel market (was US$350bn pre COVID-
19) will rise to 1.5% from ~0.4%. CTD will therefore have greater buying power and be in
a position to optimise global supplier revenue and support costs. CTD intends to overlay
its technology and business systems to increase the efficiency of T&T and its people.
acquisition will give CTD access to a world class hotel program which will further bolster
its value proposition with clients, while also being a lucrative revenue stream.
Attractive purchase price; material synergies are on offer
Consideration for T&T is US$200.4m. Due to COVID-19, CTD has been able to purchase
the business on an attractive multiple - 7.0x CY19 EBITDA of US$29m (A$41m) or 4.3x
post synergies of US$18m (A$25m). In our view, CTD’s synergy target is conservative as
it doesn’t include better buying power or technology synergies. Relative to CTD, T&T has
a low EBITDA margin (14% vs 27%), however management is targeting a similar margin
overtime. Applying CTD’s CY19 margin to T&T’s TTV of US$2.8bn (A$4.0bn) would
equate to EBITDA of US$56.3m or A$79.3m. We note CTD has a good track record of
improving the margins of its acquired businesses.
Highly EPS accretive when travel demand normalises
Like CTD, T&T can be highly profitable on domestic travel alone. Consistent with our
modelling of CTD, we assume that T&T earnings normalise to FY19 levels in FY23. We
also assume the full amount of targeted synergies (US$18m) is achieved by FY23 and
increase to US$25.5m in FY24.
Based on our FY23/24 forecasts, we believe the
acquisition is 11.7%/17.4% EPS accretive. CTD’s balance sheet is well positioned to ride
out a low revenue environment and take advantage of further M&A opportunities that may
arise (upside to our forecasts).
Investment view – Add rating
In our view, T&T is a strategically important acquisition, providing CTD’s North American
business with the necessary scale to underpin a strong competitive position which is well
placed to leverage a travel recovery post COVID-19 and therefore deliver a solid earnings
growth profile over the next few years. We upgrade to an Add rating (login to view target price).
Find out more
Morgans clients can access further analysis by browsing the latest research on our client website. If you would like access or more information, please contact your adviser or nearest Morgans office.
Need access to our research?
You are also welcome to start a two-week trial of our online platform, which provides access to detailed market analysis and insights, provided by our award-winning research team.
Create trial account
Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.